Search 

Serenatis Bio is a forward-thinking biotech company focused on revolutionising the treatment of obsessive-compulsive disorder (OCD) — a mental illness that affects hundreds of millions yet remains under-treated, despite its often devastating impact.

Serenatis Bio is advancing three novel drug candidates targeting OCD, each with unique mechanisms of action, through preclinical development. It is about to complete its pre-seed round of $1.3M, having secured $1.17M from Zinc VC (lead investor), Novaterra Ventures, the Watson Family Office, and P53 Invest. Serenatis is seeking an investor keen to put in the final $130k. 

Serenatis Bio will be launching a $30M Series A round in the second half of this year in order to go into clinical trials and would like to speak to investors interested in that round. For more information, please contact Nick Sireau, CEO and Co-founder, on nick@serenatisbio.com

Factsheet
https://biopartnermembers.meeting-mojo.com/uploads/1006/org/20250208-serenatis-bio-corporate-fact-sheet.pdf

Slide deck (non confidential)
https://biopartnermembers.meeting-mojo.com/uploads/1006/org/20250321-serenatis-bio-full-non-conf-deck-21-march-2025.pdf

• drug discovery
• mental health
• neuroscience
• small molecules
• therapeutics